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Abstract
Background Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate
cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood
mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as
the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with
high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC.
Methods Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining
resistin’s concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1
mRNA levels and rs1862513 polymorphism.
Results Plasma resistin and CAP-1 mRNA levels were higher in CRC patients (p < 0.001 and p < 0.05, respectively), while
resistin mRNA levels were lower (p < 0.001). Negative association existed among plasma resistin and HDL-C concentrations
(ρ = − 0.280; p < 0.05). A model including age, body-mass index, HDL-C, low-density lipoprotein cholesterol (LDL-C), and
plasma resistin concentrations as independent predictors of CRC showed very good diagnostic accuracy (AUC= 0.898). We
found no associations of rs1862513 with the examined markers.
Conclusions Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in
CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin’s
secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters
might be useful for prediction and prevention of CRC development.
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Introduction
Colorectal cancer (CRC) is a progressive disease, driven by
accumulated genetic and epigenetic changes and unhealthy
life habits [1]. Inflammation and adiposity are considered as
contributing factors in CRC development [2, 3], but mecha-
nisms that associate these metabolic alterations with CRC are
still not completely understood. Resistin is one of candidate
molecules that might have a significant role in the interplay of
inflammation, adiposity, and carcinogenesis. Although
resistin is considered as an adypocytokine, a translational
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study by Schwartz and Lazar implied that human resistin pri-
marily originates from macrophages, rather than from adipo-
cytes [4]. Increased resistin concentrations are commonly seen
in diabetes mellitus, metabolic syndrome, and inflammatory
bowel disease [5–7], but previous studies have also shown
that elevated resistin levels are associated with the increased
risk for development of CRC [8]. Resistin is believed to con-
tribute to cancer expansion by stimulating malignant cell
growth and proliferation, but the experiments conducted in
order to verify this hypothesis yielded contradictory results
[9]. Despite a disputable role of resistin in cell proliferation
during tumorigenesis, its relationship with inflammation in
malignant diseases is unquestionable [10]. However, it is
largely unknown whether resistin, being an adipocytokine,
also participates in development of dyslipidemia which is
commonly seen in CRC [11]. The relationship of resistin with
high-density lipoprotein (HDL) particles might be especially
intriguing, since this lipoprotein is a significant contributor to
anti-inflammatory and anti-oxidative capacities of plasma. We
have previously demonstrated alterations of high-density lipo-
protein (HDL) particles maturation, antioxidative capacity
[12], and structure [13] in CRC. Nevertheless, possible asso-
ciations of resistin with HDL cholesterol (HDL-C) concentra-
tion and paraoxonase-1 (PON-1) activity, which is an indica-
tor of HDL’s protective properties, are still unexplored in this
pathological condition. In view of cancer complexity, it was
already postulated that only a comprehensive approach, which
comprises integrative multi-parameter analysis, can lead to
thorough understanding of carcinogenesis and therefore can
assure predictive, preventive, and personalized medicine prac-
tice [14, 15]. In this context, exploration of interactions among
resistin, HDL-C and PON-1, as hallmarks of disturbed inflam-
matory, lipid, and redox balance, might be useful in defining
more accurate panel of biomarkers of increased CRC risk.
Consequently, the use of appropriate and integrated cluster
of markers could enhance disease prediction, targeted preven-
tion, and personalized treatment.
Given that the significance of resistin was confirmed in
various pathological conditions, it has been sought for an ad-
equate receptor through which resistin achieves its effects. In
humans, Toll like receptor 4 (TLR4) was considered as a prin-
cipal target for resistin’s binding [16], until Sahmin Lee et al.
discovered that adenylate cyclase-associated protein 1 (CAP-
1) can serve as a receptor for resistin [17]. The same authors
showed that resistin-CAP-1 interaction is highly capable to
activate protein kinase A (PKA) and nuclear factor kappa B
(NF-kB) signaling pathway, which further leads to inflamma-
tory cytokines production [17]. High blood concentrations of
resistin have often been associated with CRC [18], but CAP-1
gene expression was investigated in patients with cardiovas-
cular diseases [19], while resistin-CAP-1 interaction is still
unexplored in CRC. Yet, detection of plausible patterns of
alterations in protein-receptor complex could be important
for prediction of risk, prevention, and personalized treatment
of CRC, as for any other malignant disease [20]. Additionally,
modern concept of personalized medicine is mostly based on
understanding of the associations among genetic and epige-
netic alterations and individual clinical outcomes [21]. Being
one of the most common sources of genetic diversity, single
nucleotide polymorphism (SNP) analysis should not be
neglected while deriving final conclusions regarding resistin’s
role in cancer. Ample of evidences reported the association of
resistin gene (RETN) -420 C/G polymorphism (rs1862513)
with higher CRC incidence [22]. In light of this, it could be
of interest to explore the relationship among this particular
SNP and resistin protein and messenger ribonucleic acid
(mRNA) levels, as well the association with CAP-1 mRNA
levels.
The aim of our study was to investigate peripheral blood
mononuclear cells (PBMCs) resistin mRNA levels and
resistin plasma concentration, as well as PBMC CAP-1
mRNA levels in patients with CRC. Next, we investigated
the influence of RETN polymorphism rs1862513 on resistin
circulating levels and genetic markers. In addition, we ex-




This research was designed as a part of a larger project that
investigated interactive role of dyslipidemia, oxidative stress,
and inflammation in CRC, enrolling 126 patients as previous-
ly reported [12, 13]. Patients were recruited from the Clinic of
General Surgery, MilitaryMedical Academy in Belgrade from
July 2014 to January 2016. All eligible patients underwent
elective resection for CRC. Patients were enrolled according
to the following criteria: adult age, the first onset of CRC,
personal anamnesis without any previous malignant diseases,
no prior treatment with neoadjuvants, no severe physical dis-
ability, and no use of anti-hyperlipidemic drugs. Each patient
underwent postoperative histological confirmation of CRC. In
5 cases, postoperative pathohistological findings excluded
CRC, while in 121 cases, adenocarcinoma was confirmed.
Standardized questionnaires containing basic information on
age, height, weight, smoking status, physical activity, person-
al, and family anamnesis were fulfilled for each patient. Due
to incomplete data or uncompleted biochemical and genetic
analyses, 40 subjects were excluded, so the final study group
consisted of 86 patients with CRC (26 women and 60 men).
The control group included 75 healthy adults, who were
recruited during routine medical check-ups at the Medigroup
General Hospital in Belgrade. Inclusion criteria were absence
of any present or previous malignant disease; absence of
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chronic heart, liver, or kidney disease; and no use of any anti-
hyperlipidemic medications. All healthy subjects fulfilled the
same questionnaire as CRC patients. A signed informed con-
sent was obtained for every participant before the enrolment.
All procedures and study design were conducted according to
the ethical guidelines defined by the Helsinki Declaration and
approved by the local ethical committees.
Laboratory analyses
Blood samples from patients were collected immediately be-
fore surgical procedure and from healthy participants at the
commencement of a medical examination. Samples were
drawn in serum and EDTA plasma collecting vacutainers
(BD Vacutainer®, New Jersey, USA), after a 12-h fasting
period and 200 μl of whole blood were separately taken into
sterilized tubes for SNP analysis. Plasma and serum were
separated by centrifugation at 1500×g for 10 min and
15 min, respectively, and stored at − 80 °C. The samples were
analyzed immediately after thawing. Ficoll-Paque™ PLUS
(GE Healthcare, Waukesha, Wisconsin, USA) density gradi-
ent medium was used for obtaining PBMCs from EDTA
tubes. TRIzol™ (Ambion, Life technologies, Grand Island,
New York) reagent for degradation of cells and preservation
of total ribonucleic acids (tRNA) at − 80 °C was immediately
added to isolated PBMCs. Isolation of tRNAwas done accord-
ing to adjusted protocol of TRIzol™ reagent manufacturer
[23]. DNA isolation from whole blood was performed using
silica matrix columns according to the manufacturer instruc-
tions (GeneJET Whole Blood Genomic DNA Purification
Mini Kit; ThermoFisher Scientific).
Gene expression analysis and genotyping were performed
on 7500 Real-Time Polymerase Chain Reaction (PCR)
System (Applied Biosystems, Foster City, CA, USA).
Reverse transcription was achieved using High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems,
Foster City, CA, USA). Relative quantification of gene ex-
pression was performed using TaqMan™ Gene Expression
Assays (Applied Biosystems, Foster City, CA, USA). For de-
termination of human RETN levels, we used Hs00220767 m1
assay and for CAP-1, Hs00255173 m1 assay was applied,
while beta actin (Hs99999903 m1 assay) was employed as
constitutively expressed gene for gene expression data nor-
malization. The results were derived by the relative standard
curve method, while negative controls for reverse transcrip-
tion, as well as non-template controls, were used for follow-up
of reagent’s contamination. Third control was transcriptase
free control. Data are presented as a ratio of target gene
mRNA and beta actin mRNA, namely normalized resistin
mRNA = resistin mRNA/beta-actin mRNA; normalized
CAP-1 mRNA = CAP-1 mRNA/beta-actin mRNA.
Genotyping of rs1862513 (TaqMan® SNP Genotyping
Assays) was accomplished according to the instructions of
the reagent manufacturer (Applied Biosystems, Foster City,
CA, USA).
Routine laboratory assessment included determination of
total cholesterol (TC), HDL-C, low-density lipoprotein cho-
lesterol (LDL-C), and triglycerides (TG). All analyses were
pe r fo rmed on au toma t ed ana lyze r ILAB 300+
(Instrumentation Laboratory, Milan, Italy), according to the
reagent manufacturer protocols (Biosystems SA, Barcelona,
Spain). PON-1 activity was measured kinetically by the use of
substrate paraoxon. Commercial Elisa test was applied for
obtaining resistin plasma concentrations (R&D Systems,
Minneapolis, Minnesota).
Statistics
Normality of data was tested by Kolmogorov-Smirnov test.
Symmetrically distributed variables are presented as mean
± standard deviation. Parameters that followed normal dis-
tribution after logarithmic transformation are presented as
geometrical mean with 95% confidence interval. Skewed
data are presented as medians with interquartile ranges. We
used Mann-Whitney U test, Kolmogorov-Smirnov Z test,
and Kruskal-Wall is tes t for comparison of non-
symmetrically distributed data. Student’s t test was applied
for exploring differences among normally distributed var-
iables and chi-square test for analysis of categorical vari-
ables. Spearman’s correlation analysis was conducted for
evaluating statistically significant associations among the
studied parameters. Univariate binary logistic regression
analysis was applied for identification of possible risk fac-
tors for CRC development. Significant risk factors, singled
out by the univariate analysis, were further tested by mul-
tivariate binary logistic regression analysis, in order to es-
timate their independent contribution to increased risk for
CRC development. Already known anthropometric and
lipid risk factors for CRC were used as confounders in
multivariate analysis, including age, gender, BMI, HDL-
C, and LDL-C. Receiver operating characteristics (ROC)
curves were employed, and the areas under ROC curves
(AUC) were calculated for estimation of clinical accuracy
of the examined parameters. Separate ROC curves were
created for the following parameters: plasma resistin con-
centration, normalized CAP-1 mRNA, and plasma resistin/
resistin mRNA ratio. Further evaluation of diagnostic ac-
curacy was achieved for clusters of examined parameters
by formation of three different models. Model 1 included
normalized CAP-1 mRNA levels and plasma resistin con-
centration; in Model 2, we estimated discriminative ability
of combined plasma resistin, PON-1 activity, and HDL-C
concentration, while in Model 3, all independent signifi-
cant markers detected by multivariate binary regression
analysis were involved: age, BMI, HDL-C, LDL-C, and
plasma resistin concentrations. IBM® SPSS® model 22.0
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and SNPStats online software (© 2006 Institut Català
d ’Oncologia) were used for stat is t ical analyses .
Differences at p < 0.05 were considered as significant.
Results
General anthropometric and laboratory characteristics of study
participants are presented in Table 1. The age and gender
differences were statistically significant, with CRC patients
being older and more prevalent males. Body mass index
(BMI) was lower in patients. Evaluation of laboratory param-
eters singled out lower concentrations of TC, LDL-C, and
HDL-C in patient group (Table 1). Significantly higher plasma
concentrations of resistin (median 19.692 ng/mL, interquartile
range 14.192–28.282 ng/mL vs median 10.537 ng/mL, inter-
quartile range 7.838–17.860 ng/mL; p < 0.001), in parallel
with lower resistin mRNA levels (median 0.444, interquartile
range 0.312–0.643 vs median 0.693, interquartile range
0.508–1.209; p < 0.001), were observed in CRC group when
compared to controls. Plasma resistin/resistin mRNA ratio
was higher in CRC patients (median 42.519, interquartile
range 23.514–63.179), than in the control group (median
13.937, interquartile range 10.199–24.492; p < 0.001).
Higher levels of CAP-1 mRNA were also found in patients
(median 0.931, interquartile range 0.789–1.143 vs median
0.862, interquartile range 0.732–1.012; p < 0.05). Serum
PON-1 activity was higher in the control group (median
284.000 U/L, interquartile range 206.500–580.000 U/L) when
compared to CRC patients (median 204.000 U/L, interquartile
range 134.000–617.000 U/L), although with borderline statis-
tical significance according to Mann-Whitney U test (p =
0.069). However, when a more sensitive Kolmogorov-
Smirnov Z test for parameters with high inter-individual var-
iability was conducted, statistically significant difference was
achieved for comparison of PON-1 activity in CRC patients
and control subjects (p = 0.017).
Statistically significant positive correlations of plasma
resistin levels with BMI and TG were noticed in the control
group (Table 2). On the other hand, in CRC patients, a positive
association was found among BMI and CAP-1 mRNA levels,
while BMI and HDL-C were in negative correlation with
plasma resistin concentrations. In addition, a positive correla-
tion of resistin plasma levels with resistin mRNAwas noted in
patients, although without reaching statistical significance
(Table 2). Since we aimed to further investigate the observed
association among resistin protein and mRNA levels, we di-
vided CRC patients into tertiles according to plasma resistin
concentration. We observed a rise in resistin mRNA across
tertiles of plasma resistin, with statistically significant differ-
ence among the second and the third tertile (Fig. 1).
Additionally, in order to elucidate previously observed asso-
ciation among HDL-C and plasma resistin concentrations, we
divided CRC patients according to HDL-C tertiles. We ob-
served a significant increase in resistin plasma levels in the
lowest tertile, when compared to the groups with intermediate
and high levels of HDL-C (Fig. 2a). Furthermore, a positive
correlation among HDL-C and PON-1 enzyme activity, which
existed in CRC patients (ρ = 0.322; p < 0.01), led us to inves-
tigate alterations of PON-1 activity across HDL tertiles (Fig.
2b). PON-1 activity was significantly increased in the highest
HDL-C tertile group when compared to the lowest.
We also sought to explore possible independent asso-
ciations of all examined markers of resistin status with the
risk for CRC development. For that purpose, we
employed univariate and multivariate binary logistic
Table 1 General anthropometric
and laboratory data in CRC
patients and control group
Parameter CRC patients (N = 86) Control group (N = 75) p
Gender (f/m) 26/60 37/38 < 0.050
Age (years) 64.660 ± 10.999 54.670 ± 7.792 < 0.001
BMI (kg/m2) 25.105 ± 3.126 26.256 ± 3.966 < 0.050
TC (mmol/L) 4.500 ± 1.221 5.702 ± 1.029 < 0.001
HDL-C (mmol/L) 1.059 ± 0.408 1.384 ± 0.539 < 0.001
LDL-C (mmol/L) 2.841 ± 1.088 3.681 ± 0.982 < 0.001
TG (mmol/L)a 1.266 (1.176–1.364) 1.303 (1.187–1.430) 0.629
Resistin (ng/mL)b 19.692 (14.192–28.282) 10.537 (7.838–17.860) < 0.001
Normalized CAP-1 mRNAb 0.931 (0.789–1.143) 0.862 (0.732–1.012) < 0.050
Normalized resistin mRNAb 0.444 (0.312–0.643) 0.693 (0.508–1.209) < 0.001
Plasma resistin/resistin mRNAb 42.519 (23.514–63.179) 13.937 (10.199–24.492) < 0.001
PON1 activity (U/L)b 204.000 (134.000–617.000) 284.000 (206.500–580.000) 0.069
Data are presented as mean ± standard deviation and compared by Student’s t test
a Data are presented as geometrical mean (95% confidence interval for mean)
b Data are presented as median with interquartile range. Comparison was performed by Mann-Whitney U test
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regression analyses (Tables 3 and 4). Higher plasma
resistin concentrations, lower resistin mRNA, and in-
creased CAP-1 mRNA levels were singled out as possible
predictors of increased risk for CRC development in the
univariate analysis, although a wide confidence interval
(most likely due to smaller sample size) was reached in
the case of CAP-1 mRNA. After adjustment for con-
founding variables—age, gender, BMI, HDL-C, LDL-C
in multivariate analysis (Table 4)—CAP-1 mRNA lost
its predictive potential, while plasma resistin remained
statistically significant independent predictor of increased
risk for CRC development. However, the assessed odds
ratio for resistin (OR = 1.055; 95% CI 1.009–1.103) im-
plies limited contribution of this single parameter to over-
all CRC risk, whereas the entire model showed satisfying
statistical performances. Omnibus Tests of Model
Coefficients (goodness of fit test) showed high statistical
significance (p < 0.001) with χ2 value of 82.314 for 7
degrees of freedom (df). Hosmer-Lemeshow goodness of
fit test, for constructed model, was satisfying (χ2 = 7.252;
df = 8; p = 0.510), while value of Nagelkerke R Square
was 0.596. The obtained accuracy in classification was
82.7%. Normalized resistin mRNA was not included in a
model since it did not satisfy Hosmer-Lemeshow good-
ness of fit requirement in univariate logistic regression
(p < 0.001).
Next, we estimated clinical accuracy of investigated pa-
rameters and clusters of parameters (Table 5). AUC > 0.7
was obtained for all investigated markers except for CAP-1
mRNA, while AUC > 0.8 was obtained for plasma resistin/
resistin mRNA ratio and combination of all independent pre-
dictors of CRC identified in previous logistic regression anal-
ysis (age, BMI, HDL-C, LDL-C, and plasma resistin
concentrations).
Finally, we analyzed the association among RETN poly-
morphism rs1862513 and other examined resistin-linked pa-
rameters. Hardy-Weinberg’s equilibrium existed in both our
cohorts [CRC group: χ2 = 1.196 p = 0.274 for subsequent ge-
notype distribution (expressed as relative frequencies) CC =
0.55; CG = 0.35; GG = 0.1], [control group: χ2 = 0.525 p =
Table 2 Significant correlations
of plasma resistin and normalized
CAP1 mRNA levels with other
examined parameters in CRC
patients and control group
Parameter Resistin (ng/mL) Normalized CAP-1 mRNA
CRC patients
BMI (kg/m2) ρ = − 0.245; p < 0.050 ρ = 0.222; p = 0.050
HDL-C (mmol/L) ρ = − 0.280; p < 0.050 ρ = 0.062; p = 0.571
Normalized resistin mRNA ρ = 0.204; p = 0.076 ρ = 0.083; p = 0.458
Control group
BMI (kg/m2) ρ = 0.434; p < 0.001 ρ = 0.069; p = 0.564
TG (mmol/L) ρ = 0.277; p < 0.050 ρ = 0.003; p = 0.977
Normalized resistin mRNA ρ = 0.078; p = 0.521 ρ = 0.132; p = 0.259
























Fig. 1 Changes in PBMC resistin
mRNA levels across tertile of
plasma resistin concentration in
patients with colorectal cancer
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0.469 for subsequent genotype distribution (expressed as rel-
ative frequencies) CC = 0.57; CG = 0.35; GG = 0.08]. CRC
and control groups did not differ regarding genotype distribu-
tion (χ2 = 0.210; p = 0.900). Kruskal-Wallis test demon-
strated that there were no differences in resistin plasma
concentration, resistin mRNA, and CAP-1 mRNA levels
among subjects with CC, CG, and GG genotypes, neither
in CRC patients (resistin: p = 0.361; resistin mRNA: p =
0.509; CAP-1 mRNA: p = 0.147), nor in the control
group (resistin: p = 0.439; resistin mRNA: p = 0.074;
CAP-1 mRNA: p = 0.860).
Discussion
In this study, the relationship among plasma resistin concen-
tration, resistin mRNA, and CAP-1 mRNA levels were inves-
tigated for the first time in CRC patients. Our results showed
higher plasma resistin concentration, followed by lower
resistin mRNA levels in CRC patients. Additionally, higher
CAP-1 mRNAwas demonstrated in CRC group.
Recently, a study performed on monocytes suggested that
CAP-1 is a receptor for human resistin [17], but a limited



















































Tertile groups of HDL-C (mmol/L)
Fig. 2 Changes in plasma resistin
concentrations and PON1
activities across tertile of HDL-C
concentration in patients with co-
lorectal cancer. a) Changes in
plasma resistin concentrations
across tertile of HDL-C concen-
tration. b) Changes in PON-1 ac-
tivities across tertile of HDL-C
concentration
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interactions in malignant diseases. In contrast, the effects me-
diated by the association of resistin with TLR4 were exten-
sively reviewed. Wang et al. have demonstrated that resistin-
TLR4 interaction in carcinoma cell lines has tumor-promoting
effects during the development of breast cancer [24]. It was
also suggested that in gastric carcinoma cells, resistin stimu-
lates angiogenesis through TLR4-mediated effects [25].
Nevertheless, it has been shown that immunohistochemical
staining for CAP-1 protein is positive in over 50% of CRC
tissue samples [26], thus implicating that CAP-1-resistin in-
teraction might play important role in this disease develop-
ment. It has been already demonstrated that CAP-1 tissue
mRNA overexpression is associated with lower surviving rate
in breast and ovarian cancers [27]. As an actin binding protein
[28], CAP-1 was considered as a metastasis promoting factor,
as well as cancer invasiveness mediator [26, 27]. In our cur-
rent study, CAP-1 mRNA levels were evaluated and found to
be higher in CRC patients (Table 1). Concomitantly higher
plasma resistin concentrations (Table 1) might indicate signif-
icant resistin-CAP-1 interaction in CRC, which should be fur-
ther explored. Based on our preliminary findings in CRC pa-
tients, we could hypothesize a presence of a characteristic
pattern of resistin-CAP-1 interaction, which is different from
well-known resistin-TRL4 cooperation and might be of po-
tential interest as either biomarker or therapeutic target. It has
been previously demonstrated that association of resistin with
CAP-1 in monocytes leads to increased production of pro-
inflammatory cytokines [17]. Since these cytokines enhance
PBMC resistin mRNA expression [29], a positive feedback
loop can be made, thereby further promoting pro-
inflammatory environment necessary for the onset of CRC.
Although pro-inflammatory role of resistin is especially
emphasized in numerous studies, its negative correlation with
HDL-C was also observed in different pathological condi-
tions, including CRC [30]. This correlation was singled out
as a significant one in our patients as well (Table 2; Fig. 2a).
The mechanism through which HDL can inhibit the produc-
tion of resistin has already been proposed. Namely, it has been
shown in 3T3L1 murine adipocytes that HDL particles inter-
act with oxidized LDL causing lower free cholesterol accu-
mulation and reduced endoplasmic reticulum stress, which
consequently leads to decreased adipocytokine secretion
[31]. Although significant discrepancy among human and
mouse resistin prevents deriving definitive conclusions, these
findings suggest that elevation of circulating resistin levels in
humans might arise as a consequence of decreased HDL-C
and impaired HDL particle functionality. In our previous
study, we demonstrated that HDL particle distribution in pa-
tients with CRC is characterized by lower diameter and in-
creased proportion of smaller HDL3b particles, implying
compromised HDL functionality [13]. Accordingly, in the
current study, we found a change in PON-1 activity across
tertiles of HDL-C (Fig. 2b). Since PON-1 is an HDL-
associated enzyme, responsible for degradation of oxidized
lipids within LDL, it can be hypothesized that dysfunctional
HDL particles in CRC are unable to prevent an increase in
resistin secretion. On the other hand, resistin promotes forma-
tion of pro-inflammatory environment, which can further di-
minish HDL functionality [32], thus contributing to aggrava-
tion of the initial pathological process. Recently, Lu and Zhan
pointed out to the importance of multi-parameter model in
understanding of cancer complexity and detecting of reliable
biomarkers [14]. The observed association among plasma
Table 3 Univariate binary logistic regression analysis for the
associations of plasma resistin concentration, normalized resistin
mRNA and CAP1 mRNA levels with the risk for CRC onset
Parameter OR 95% CI p
Resistin (ng/mL) 1.071 1.031–1.112 < 0.001
Normalized resistin mRNA 0.325 0.160–0.661 < 0.010
Normalized CAP-1 mRNA 4.476 1.124–17.824 < 0.050
Variables are entered as continuous
Table 4 Multivariate binary regression analysis for independent
associations of plasma resistin concentration with risk for development
of CRC
Parameter OR 95% CI p
Age (years) 1.132 1.071–1.196 < 0.001
Gender (f/m) 1.366 0.477–3.907 0.561
BMI (kg/m2) 0.800 0.688–0.931 < 0.010
HDL-C (mmol/L) 0.263 0.092–0.748 < 0.050
LDL-C (mmol/L) 0.449 0.282–0.715 < 0.001
Resistin (ng/mL) 1.055 1.009–1.103 < 0.050
Normalized CAP-1 mRNA 5.409 0.645–45.376 0.120
Variables are entered as continuous, except for gender. Enter model
Table 5 Areas of ROC (AUC) for estimation of clinical accuracy of
examined parameters
Parameter AUC CI p
Resistin (ng/mL) 0.741 0.663–0.820 < 0.001
Normalized CAP-1 mRNA 0.603 0.515–0.690 < 0.050
Plasma resistin/resistin mRNA 0.821 0.754–0.889 < 0.001
Model 1 0.748 0.668–0.828 < 0.001
Model 2 0.757 0.671–0.843 < 0.001
Model 3 0.898 0.845–0.950 < 0.001
Model 1: normalized CAP-1 mRNA+ resistin (ng/mL)
Model 2: resistin (ng/mL) + PON1 activity (U/L) + HDL-C (mmol/L)
Model 3: included all independent predictors of CRC as detected by
multivariate logistic regression analysis (age (years) + BMI (kg/m2 ) +
HDL-C (mmol/L) + LDL-C (mmol/L) + resistin (ng/mL))
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resistin, HDL-C, and PON-1 activity in CRC confirms such
point of view and underline its importance for better under-
standing, and consequently, efficient prediction and preven-
tion of CRC development.
Although macrophages are the main source of plasma
resistin in humans, PBMCs, namely monocytes and lympho-
cytes, also produce resistin and thereby contribute to overall
plasma resistin concentration [33]. However, determination of
PBMC resistin mRNA levels in our study yielded unexpected
results. In contrast to higher plasma resistin concentration, we
have found lower PBMC resistin mRNA levels in CRC pa-
tients (Table 1). A possible reason for such discrepancy could
be found in diverse resistin productions by PBMCs and ma-
lignant tissue. It has been suggested that increased resistin
secretion in CRC could be attributed to tumor-infiltrating
macrophages, rather than to malignant cells themselves [34].
Additionally, a recent study in women with breast cancer dem-
onstrated that serum resistin concentration was not correlated
with its gene expression in cancerous tissue [35]. In contrast to
a longstanding opinion according to which macrophages orig-
inates exclusively from blood monocytes, it has been demon-
strated that precursors of tissue-resident macrophages are pro-
genitor cells from yolk sac and fetal liver [36]. On the other
side, monocyte-derived macrophages become abundant in tis-
sues during inflammatory response [36]. Having in mind that
chronic inflammation is associated with CRC [37], it can be
assumed that the observed higher plasma resistin levels in our
patients arise as a consequence of its increased production by
highly abundant tumor-associated macrophages. Yet, we
found a borderline significant positive correlation of resistin
mRNA with plasma resistin concentration in CRC patients
(Table 2). In addition, we observed an increase in resistin
mRNA across tertiles of plasma resistin (Fig. 1). Altogether,
we can presume that PBMCs are contributors to circulating
resistin level, but not the only ones and likely not the most
significant ones in CRC. The obtained results led us to the
hypothesis that the discrepancy between plasma resistin and
PBMC mRNA resistin levels might be used as a potential
indicator of CRC development. We therefore calculate and
analyzed plasma resistin/resistin mRNA ratio. As a confirma-
tion of our hypothesis, we found significantly higher values of
plasma resistin/resistin mRNA ratio in CRC patients (Table 1).
Furthermore, this ratio exhibited high discriminative abilities
for CRC (Table 5). Such findings might have important con-
sequences for potential use of resistin protein and mRNA
levels in diagnosis and prognosis of CRC. Namely, increased
plasma resistin and plasma resistin/resistin mRNA ratio might
be considered as easily detectable candidate markers of CRC
development and progression. Thus, methods of molecular
biology and genetic tests can complement and improve tradi-
tional biochemical determination of protein levels, as already
postulated [38]. Additionally, this ratio can be easily deter-
mined in samples obtained by a simple venepuncture, which
could present a significant advantage for potential clinical use.
Nevertheless, our preliminary findings should be further test-
ed and evaluated by basic and clinical studies.
In spite of still unresolved questions regarding the exact
role of resistin in colorectal carcinogenesis, higher resistin
levels in CRC are reported in large number of studies [18].
An association among tumor stage and serum resistin concen-
trations has been shown [30] and possible use of resistin as a
marker for CRC was emphasized [39]. In light of these evi-
dences, we examined the predictive potential of plasma
resistin, PBMC resistin mRNA and CAP-1 mRNA levels for
CRC development. All three parameters individually had a
significant predictive potential (Table 3), while in multivariate
binary logistic regression, which included age, gender, BMI,
LDL-C, HDL-C, and normalized CAP1 mRNA as con-
founders, resistin remained a significant predictor of CRC risk
(Table 4). Although the obtained odds ratio (OR = 1.055; 95%
CI 1.009–1.103) suggests minor involvement of plasma
resistin in elevation of CRC risk, the obtained statistical sig-
nificance still indicates independent contribution of resistin to
the development of this disease. In addition, our preliminary
findings demonstrated that clinical accuracy of resistin was
comparable with currently used tumor markers for CRC, such
as serum CA 19-9 and CEA [40]. Moreover, clustering of
resistin with resistin mRNA and several easily obtainable an-
thropometric and laboratory data (age, BMI, LDL-C and
HDL-C) yielded sufficiently high clinical accuracy
(Table 5), emphasizing the importance of a multi-marker ap-
proach in prediction and diagnosis of CRC. Taken altogether,
resistin protein and mRNA levels might be proposed as can-
didate biomarkers for CRC, which should be further
evaluated.
Previous studies linked RETN polymorphism rs1862513
(− 420 C/G) with higher concentration of resistin and conse-
quently with aggravated pro-inflammatory status in patients
with CRC and breast cancer, emphasizing GG allelic variant
of gene as a dominant for these effects [22]. Osawa et al.
showed the association among RETN rs1862513 polymor-
phism in promoter region and enhanced resistin mRNA ex-
pression due to the altered binding of Sp1/3 transcriptional
factors [41]. However, the same authors suggested the pres-
ence of other significant SNPs, proposing that multiple effects
of different alleles have to be taken into account [42].
Additionally they demonstrated that methylation at SNP-420
was associated with lower resistin’s concentration in CC and
CG genotypes [43]. In our current study, we did not find any
association of altered resistin and CAP-1 gene expression
levels or plasma resistin concentration with RETN
rs1862513 polymorphism. In addition, we found no differ-
ences regarding allelic distribution in CRC patients and
healthy individuals. Taken altogether, we can assume that lack
of association among this specific SNP and resistin gene ex-
pression and protein concentration in our CRC patients might
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be a consequence of other genetic or epigenetic effects that go
beyond a single genetic change, emphasizing the importance
of more comprehensive approach to genetic analyses.
Several limitations should be mentioned. First, the ob-
served discrepancy among plasma resistin and PBMCs
resistin mRNA levels cannot be fully explained without an
insight into resistin concentration and gene expression in can-
cerous tissue. In the current study, we used blood samples, so
we could not perform such analyses. Also, comparison of our
current results with findings of previous studies is partially
limited by the fact that majority of other studies utilized tissue
samples or cell cultures. However, a plausible use of resistin as
a prognostic marker would include less invasive techniques,
such is venepuncture, and thus investigations in blood sam-
ples are rationale and needed. Next, the observational study
design does not allow drawing a conclusion regarding causa-
tive relationship among resistin level and CRC development.
In addition, relatively small sample size limited deriving firm
conclusions regarding the observed associations. Longitudinal
studies with larger sample size are needed to verify our pre-
liminary findings.
Conclusions and expert recommendations
Our study demonstrated higher plasma resistin and PBMCs
CAP-1 mRNA levels in patients with CRCwhen compared to
healthy individuals, implying their possible interaction during
the onset of this malignancy. Lack of concomitant increase in
resistin mRNA levels suggests that overproduction of resistin
in CRC is related to other sources, most likely tumor-
associated macrophages, than to circulating PBMCs. In addi-
tion, plasma resistin concentration and plasma resistin/PBMC
resistin mRNA ratio were revealed as potentially useful diag-
nostic and prognostic tools. Finally, the observed associations
among resistin and HDL-C raise the possibility that a delicate
interplay among these two markers of dyslipidemia and in-
flammation participates in pathogenesis of CRC, which
should be further explored and evaluated by future studies.
In our research, we used plasma and PBMCs collected by a
simple venepuncture, which is minimally invasive, rapid, and
inexpensive procedure for acquiring of appropriate and repre-
sentative samples. Our results suggest that such easily obtain-
able samples could provide clusters of integrated biomarkers
related to CRC, with significant predictive abilities and satis-
fying clinical accuracy. Therefore, minimally onerous and rel-
atively comfortable sampling procedure could ensure multi-
marker strategy which is a hallmark of preventive, predictive,
and personalized medicine practice. Additionally, our findings
implicate that evaluation of protein concentration should be
complemented with molecular detection, in order to obtain an
insight into possible deregulation regarding protein coding,
posttranscriptional and posttranslational modifications and in-
teractions with receptors.
In summary, resistin protein and PBMC mRNA levels
might be considered as potential candidate biomarkers for
CRC. Further evaluation of these parameters is necessary to
assure the most reliable conclusion regarding the implemen-
tation of these analyses in routine clinical laboratories. In ad-
dition to all requirements of good laboratory practice, a cost-
efficacy analysis is needed for precise estimation of benefits
that could be achieved by implementation of these markers.
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